drugset / Trial / NCT05420324
A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, single-arm, open-label phase II study to assess the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.
Timeline
- Start
- 2022-06-13
- Primary completion
- 2024-03-04
- Completion
- 2024-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YH003 | Unknown | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |